Mice lacking the Irg1 gene exhibited decreased tumor growth, reduced immunosuppressive activity of MDSCs, enhanced CD8+ T-cell-mediated anti-tumor immunity, and improved responses to anti-PD-1 therapy [144]. This evidence concerns the gene CD8A and neoplasm.